Arch Therapeutics, Inc.
ARTH · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.03 | -0.33 | 0.01 |
| FCF Yield | -22.30% | -8.65% | -2.53% | -20.20% |
| EV / EBITDA | -2.70 | -18.41 | -27.55 | -8.84 |
| Quality | ||||
| ROIC | 32.20% | 31.10% | 65.18% | 81.20% |
| Gross Margin | 31.81% | 32.36% | 48.53% | 41.09% |
| Cash Conversion Ratio | 0.16 | 0.48 | 0.32 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 111.54% | 140.44% | 92.13% | 87.08% |
| Free Cash Flow Growth | -30.20% | 18.83% | 29.94% | -37.18% |
| Safety | ||||
| Net Debt / EBITDA | -1.88 | -9.17 | -4.74 | -4.25 |
| Interest Coverage | -1.52 | -1.48 | -1.26 | -1.18 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.02 | 0.02 | 0.02 |
| Cash Conversion Cycle | -6,815.98 | -6,847.29 | -5,477.07 | -3,632.72 |